Brain+ A/S (BRAINP.CO)
- Previous Close
0.0138 - Open
0.0138 - Bid 0.0184 x --
- Ask 0.0230 x --
- Day's Range
0.0138 - 0.0258 - 52 Week Range
0.0119 - 0.2000 - Volume
18,289,441 - Avg. Volume
2,812,364 - Market Cap (intraday)
15.013M - Beta (5Y Monthly) -0.34
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Brain+ A/S develops digital therapeutics for Alzheimer's and dementia. The company's product pipeline includes cognitive stimulation therapy (CST) - Therapist Companion, an application that enables therapists to deliver CST while saving significant preparation time; CST - Home Companion, a digital health application to provide repeat exposure to the CST program in an at-home setting during and after participation in a therapist facilitated CST program; CST - Home Care, a solution to enable people with dementia to continue to receive maintenance benefits from CST therapy after completion of the seven-week basic CST group program; and CST for mild cognitive impairment (MCI), a solution for individuals with MCI, offering an adapted version of CST to address their unique needs. It also develops Computerized Cognitive Training, a cognitive training method for patients with mild cognitive impairment; and Starry Night, a memory test designed to identify early signs of Alzheimer's disease. The company was incorporated in 2012 and is based in Copenhagen, Denmark.
www.brain-plus.com20
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BRAINP.CO
View MorePerformance Overview: BRAINP.CO
Trailing total returns as of 6/6/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BRAINP.CO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BRAINP.CO
View MoreValuation Measures
Market Cap
15.01M
Enterprise Value
14.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.37
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-7.60%
Return on Assets (ttm)
-1.60%
Return on Equity (ttm)
-7.15%
Revenue (ttm)
6.08M
Net Income Avi to Common (ttm)
-462.19k
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--